|
May 5
|
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
|
|
Apr 2
|
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
|
|
Mar 27
|
Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck
|
|
Mar 26
|
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
|
|
Dec 20
|
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
|
|
Nov 28
|
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
|
|
Nov 27
|
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
|